GlaxoSmithKline plc (LON:GSK) had its price objective reduced by investment analysts at J P Morgan Chase & Co from GBX 1,750 ($22.60) to GBX 1,570 ($20.28) in a report released on Wednesday. The brokerage currently has a “neutral” rating on the stock. J P Morgan Chase & Co’s target price would suggest a potential upside of 4.91% from the stock’s previous close.
A number of other research firms have also recently weighed in on GSK. S&P Global set a GBX 1,500 ($19.37) target price on shares of GlaxoSmithKline plc and gave the company a “sell” rating in a research note on Tuesday, June 6th. UBS AG set a GBX 1,600 ($20.66) target price on shares of GlaxoSmithKline plc and gave the company a “neutral” rating in a research note on Wednesday, July 26th. Shore Capital restated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Friday, June 2nd. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($24.54) target price on shares of GlaxoSmithKline plc and gave the company a “buy” rating in a research note on Tuesday, August 8th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a GBX 1,900 ($24.54) price target on shares of GlaxoSmithKline plc in a report on Thursday, July 13th. Four research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have given a buy rating to the company. GlaxoSmithKline plc has a consensus rating of “Hold” and an average target price of GBX 1,705.90 ($22.03).
GlaxoSmithKline plc (LON GSK) opened at 1496.50 on Wednesday. GlaxoSmithKline plc has a 1-year low of GBX 1,446.50 and a 1-year high of GBX 1,745.56. The company has a 50-day moving average price of GBX 1,515.32 and a 200-day moving average price of GBX 1,613.58. The company’s market cap is GBX 73.15 billion.
COPYRIGHT VIOLATION NOTICE: “GlaxoSmithKline plc (GSK) PT Lowered to GBX 1,570 at J P Morgan Chase & Co” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/2887650/glaxosmithkline-plc-gsk-pt-lowered-to-gbx-1570-at-j-p-morgan-chase-co.html.
In other news, insider Manvinder Singh Banga purchased 2,267 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The shares were bought at an average cost of GBX 1,599 ($20.65) per share, for a total transaction of £36,249.33 ($46,815.61). Also, insider Victoria Whyte sold 4,820 shares of the company’s stock in a transaction dated Tuesday, June 20th. The shares were sold at an average price of GBX 1,693 ($21.86), for a total transaction of £81,602.60 ($105,388.87). Insiders have purchased a total of 3,152 shares of company stock worth $5,055,023 over the last quarter.
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.